Latest news

PentixaPharm thumbnail news.jpg 15 May 2019

Scintomics and 1717 Life Science Ventures Team up

Scintomics and 1717 LSV to collaborate in the development of novel cancer diagnostics and treatment.

Read more
Blue-Earth logo 900400.jpg 2 May 2018

Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics

Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.

Read more